AMBS News Alert Amarantus Biosci Inc (AMBS) 0.0822 01/01/2015
Post# of 64074
Posted On: 01/01/2015 3:51:23 PM
Amarantus Biosci Inc (AMBS) 0.0822 $AMBS
Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
GlobeNewswire - Mon Dec 29, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced it will be presenting a corporate overview including top-line results of its expanded LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD) at Biotech Showcase 2015. Gerald E. Commissiong, President & CEO of Amarantus, will present on Wednesday, January 14, 2015 at the Parc 55 Wyndham Union Square in San Francisco, CA.
Amarantus' MANF an Orphan Drug for degenerative eye disease
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:41PM CST
Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
GlobeNewswire - Tue Dec 23, 3:00PM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted the company's investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) orphan drug designation for the treatment of Retinitis Pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness.
Amarantus BioScience Holdings, Inc. - "Amarantus Diagnostics: Launching our First Product in the Neurodiagnostics Marketâ??"
ACCESSWIRE - Mon Dec 22, 10:25AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus anticipates additional USD2.0m through second closing of Series E Preferred financing
M2 - Mon Dec 22, 6:38AM CST
Biotechnology company Amarantus BioScience Holdings (Other OTC:AMBS) said on Friday that it expects to raise an additional USD2.0m through the issue of shares of Series E preferred stock.
Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
GlobeNewswire - Mon Dec 22, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced the launch of the company's LymPro Test, a leading, proprietary Alzheimer's blood diagnostic, to the pharmaceutical industry for investigational use in clinical development programs. The commercialization of LymPro follows the successful completion of the requisite 'Fit-for-Purpose' assay validation conducted at Icon Central Laboratories.
Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
GlobeNewswire - Fri Dec 19, 6:35AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
Amarantus Announces Second Closing of Series E Preferred Financing
GlobeNewswire - Fri Dec 19, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has entered into definitive agreements to raise an additional $2.0 million under its previously announced transaction to issue shares of Series E Preferred Stock (the "Series E"
, bringing the total capital raised to $5.0 million. The second closing was led by International Infusion.
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 31.68 (-0.33), CHTP: 6.52 (-0.03), SUPN: 8.30 (+0.16), ITCI: 17.65 (-0.35), LLY: 68.99 (-0.65), DRRX: 0.79 (+0.02)
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
M2 - Thu Dec 11, 9:04AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTCBB: AMBS) after releasing the latest short sale data through December 10, 2014. The total aggregate number of shares shorted since June 2011 is approximately 1.31 billion shares. Approximately 30.66% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.078. A short squeeze is imminent as AMBS is above its SqueezeTrigger Price.
Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
GlobeNewswire - Thu Dec 11, 7:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced the appointment of Elise Brownell, Ph.D., to the newly created position of Senior Vice President of Operations and Program Management.
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5mzsz/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acucela - Amarantus Bioscience - Applied Genetic - Asklepios BioPharmaceutical - BBB Therapeutics - BioDiem - DNAVEC - Dompe Farmaceutici - Genable Technologies - GenSight Biologics - Grupo Ferrer Internacional - International Stem Cell Corporation - Mimetogen - NeoStem - Neurotech - Ocata - Orphagen - QLT - R-Tech Ueno - ReGenX Biosciences - ReNeuron - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/w5mzsz/retinitis
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
GlobeNewswire - Mon Dec 08, 7:17AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced the appointment of Joseph Rubinfeld, Ph.D. to its Board of Directors. Dr. Rubinfeld is a renowned expert in the field of drug development, and a co-founder of Amgen, one of the most successful companies in the history of the biotechnology industry. Dr. Rubinfeld brings more than 40 years of biopharmaceutical leadership experience to Amarantus' Board of Directors.
AMGN: 159.29 (-1.34)
Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
GlobeNewswire - Tue Nov 25, 8:38AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced positive effects of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the protection from vision loss in an animal model of retinitis pigmentosa (RP). MANF was discovered utilizing Amarantus' proprietary PhenoGuard(TM) Protein Discovery Engine.
Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014
GlobeNewswire - Mon Nov 24, 7:01AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a diversified biotechnology company focused on the development of diagnostic and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine announced today that Gerald E. Commissiong, President and Chief Executive Officer, will present at the LD Micro Main Event VII micro-cap investor conference being held December 2 - 4, 2014 at the Luxe Sunset Hotel in Los Angeles, California.
Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease
GlobeNewswire - Thu Nov 20, 9:12AM CST
-- Full dataset on 140 patients in mild, moderate and severe Alzheimer's disease subjects expected to be announced in December 2014
Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
PR Newswire - Wed Nov 19, 11:46AM CST
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that it has entered into an Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. ("Amarantus" . Under the agreement, Amarantus acquires Regenicin rights and claims in the company's litigation currently pending against Lonza Walkersville and Lonza America, Inc. This included all of Regenicin's Cutanagen intellectual property rights and any Lonza manufacturing know-how technology Regenicin may have. In addition, Regencin will sell to Amarantus its PermaDerm trademark and related intellectual property rights associated with it.
Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Thomson Reuters ONE - Mon Nov 17, 3:20PM CST
- Engineered Skin substitute (ESS): Phase 1/ Early Phase 2 product candidate that has potential to be a revolutionary new treatment for severe burns
Amarantus to Host Business Update Conference Call on November 18, 2014
GlobeNewswire - Mon Nov 17, 7:19AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a diversified biotechnology company focused on the development of diagnostic and therapeutic products in the areas of neurology, psychiatry and ophthalmology announced today that it plans to host a conference call with the investment community on Tuesday, November 18, 2014.
Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
GlobeNewswire - Mon Dec 29, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced it will be presenting a corporate overview including top-line results of its expanded LP-002 study of the Lymphocyte Proliferation Test (LymPro Test) blood diagnostic for Alzheimer's disease (AD) at Biotech Showcase 2015. Gerald E. Commissiong, President & CEO of Amarantus, will present on Wednesday, January 14, 2015 at the Parc 55 Wyndham Union Square in San Francisco, CA.
Amarantus' MANF an Orphan Drug for degenerative eye disease
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 3:41PM CST
Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
GlobeNewswire - Tue Dec 23, 3:00PM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted the company's investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) orphan drug designation for the treatment of Retinitis Pigmentosa (RP). RP refers to a group of inherited diseases causing retinal degeneration often leading to blindness.
Amarantus BioScience Holdings, Inc. - "Amarantus Diagnostics: Launching our First Product in the Neurodiagnostics Marketâ??"
ACCESSWIRE - Mon Dec 22, 10:25AM CST
NEW YORK, NY / ACCESSWIRE / December 22, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Amarantus anticipates additional USD2.0m through second closing of Series E Preferred financing
M2 - Mon Dec 22, 6:38AM CST
Biotechnology company Amarantus BioScience Holdings (Other OTC:AMBS) said on Friday that it expects to raise an additional USD2.0m through the issue of shares of Series E preferred stock.
Amarantus Commences Launch of Proprietary Alzheimer's Blood Diagnostic LymPro Test(R) to Pharmaceutical Industry for Use in Clinical Trials
GlobeNewswire - Mon Dec 22, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced the launch of the company's LymPro Test, a leading, proprietary Alzheimer's blood diagnostic, to the pharmaceutical industry for investigational use in clinical development programs. The commercialization of LymPro follows the successful completion of the requisite 'Fit-for-Purpose' assay validation conducted at Icon Central Laboratories.
Amarantus Submits Orphan Drug Designation Application to US FDA for Treatment of Retinal Artery Occlusion With Product Candidate MANF
GlobeNewswire - Fri Dec 19, 6:35AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has applied to the U.S. Food & Drug Administration (FDA) for Orphan Drug Designation for its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) as a treatment for retinal artery occlusion (RAO). RAO is a blockage of the blood supply to the retina which causes severe and sudden loss of vision.
Amarantus Announces Second Closing of Series E Preferred Financing
GlobeNewswire - Fri Dec 19, 6:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it has entered into definitive agreements to raise an additional $2.0 million under its previously announced transaction to issue shares of Series E Preferred Stock (the "Series E"
, bringing the total capital raised to $5.0 million. The second closing was led by International Infusion. Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 31.68 (-0.33), CHTP: 6.52 (-0.03), SUPN: 8.30 (+0.16), ITCI: 17.65 (-0.35), LLY: 68.99 (-0.65), DRRX: 0.79 (+0.02)
BUYINS.NET Updates Amarantus BioSciences SqueezeTrigger Report
M2 - Thu Dec 11, 9:04AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has updated coverage on Amarantus BioSciences (OTCBB: AMBS) after releasing the latest short sale data through December 10, 2014. The total aggregate number of shares shorted since June 2011 is approximately 1.31 billion shares. Approximately 30.66% of daily trading volume is short selling. The SqueezeTrigger price for all AMBS shares shorted is $0.078. A short squeeze is imminent as AMBS is above its SqueezeTrigger Price.
Amarantus Appoints Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management
GlobeNewswire - Thu Dec 11, 7:00AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced the appointment of Elise Brownell, Ph.D., to the newly created position of Senior Vice President of Operations and Program Management.
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5mzsz/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acucela - Amarantus Bioscience - Applied Genetic - Asklepios BioPharmaceutical - BBB Therapeutics - BioDiem - DNAVEC - Dompe Farmaceutici - Genable Technologies - GenSight Biologics - Grupo Ferrer Internacional - International Stem Cell Corporation - Mimetogen - NeoStem - Neurotech - Ocata - Orphagen - QLT - R-Tech Ueno - ReGenX Biosciences - ReNeuron - Sanofi - Shire For more information visit http://www.researchandmarkets.com/research/w5mzsz/retinitis
Amarantus Appoints Renowned Drug Development Expert and Co-Founder of Amgen, Joseph Rubinfeld, Ph.D., to Its Board of Directors
GlobeNewswire - Mon Dec 08, 7:17AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced the appointment of Joseph Rubinfeld, Ph.D. to its Board of Directors. Dr. Rubinfeld is a renowned expert in the field of drug development, and a co-founder of Amgen, one of the most successful companies in the history of the biotechnology industry. Dr. Rubinfeld brings more than 40 years of biopharmaceutical leadership experience to Amarantus' Board of Directors.
AMGN: 159.29 (-1.34)
Amarantus Announces Positive Preclinical Data on the Effects of MANF on Vision in a Model of Retinitis Pigmentosa
GlobeNewswire - Tue Nov 25, 8:38AM CST
Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced positive effects of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the protection from vision loss in an animal model of retinitis pigmentosa (RP). MANF was discovered utilizing Amarantus' proprietary PhenoGuard(TM) Protein Discovery Engine.
Amarantus to Present at the LD Micro Main Event VII Investor Conference on December 2, 2014
GlobeNewswire - Mon Nov 24, 7:01AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a diversified biotechnology company focused on the development of diagnostic and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine announced today that Gerald E. Commissiong, President and Chief Executive Officer, will present at the LD Micro Main Event VII micro-cap investor conference being held December 2 - 4, 2014 at the Luxe Sunset Hotel in Los Angeles, California.
Amarantus Completes Enrollment of Expanded LP-002 Study of Alzheimer's Blood Diagnostic LymPro Test(R) to Assess Predictive Value in Early-Stage Disease
GlobeNewswire - Thu Nov 20, 9:12AM CST
-- Full dataset on 140 patients in mild, moderate and severe Alzheimer's disease subjects expected to be announced in December 2014
Regenicin Enters Into Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc.
PR Newswire - Wed Nov 19, 11:46AM CST
Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of and commercialization of regenerative cell therapies to restore the health of damaged tissues and organs, announced today that it has entered into an Asset Purchase Agreement with Amarantus Bioscience Holdings, Inc. ("Amarantus"
. Under the agreement, Amarantus acquires Regenicin rights and claims in the company's litigation currently pending against Lonza Walkersville and Lonza America, Inc. This included all of Regenicin's Cutanagen intellectual property rights and any Lonza manufacturing know-how technology Regenicin may have. In addition, Regencin will sell to Amarantus its PermaDerm trademark and related intellectual property rights associated with it. Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Thomson Reuters ONE - Mon Nov 17, 3:20PM CST
- Engineered Skin substitute (ESS): Phase 1/ Early Phase 2 product candidate that has potential to be a revolutionary new treatment for severe burns
Amarantus to Host Business Update Conference Call on November 18, 2014
GlobeNewswire - Mon Nov 17, 7:19AM CST
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a diversified biotechnology company focused on the development of diagnostic and therapeutic products in the areas of neurology, psychiatry and ophthalmology announced today that it plans to host a conference call with the investment community on Tuesday, November 18, 2014.
(0)
(0)Scroll down for more posts ▼